Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-09 pm EDT			5-day change	1st Jan Change
13.83 ^USD	-0.29%		+5.33%	+53.84%

Mar. 06	Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
Mar. 03	Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran	CI

Transcript : Intellia Therapeutics, Inc., Q4 2025 Earnings Call, Feb 26, 2026

Published on 02/26/2026 at 05:08 pm EST - Modified on 02/26/2026 at 10:32 pm EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Hello, and welcome to Intellia Therapeutics' Fourth Quarter and Full Year 2025 Conference Call. My name is Drew, and I will be your conference operator

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Intellia Therapeutics, Inc.

Mar. 06	Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
Mar. 03	Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran	CI
Mar. 03	Chardan Raises Price Target on Intellia Therapeutics to $27 From $26, Keeps Buy Rating	MT
Mar. 03	RBC Raises Price Target on Intellia Therapeutics to $15 From $9, Keeps Sector Perform, Speculative Risk	MT
Mar. 02	William Blair Upgrades Intellia Therapeutics to Outperform From Market Perform	MT
Mar. 02	Global markets live: Amazon, AWS, Lufthansa, Saudi Aramco, Standard Chartered…
Mar. 02	Intellia Therapeutics Says US FDA Removes Clinical Hold on Magnitude Phase 3 Trial for Nexiguran Ziclumeran	MT
Mar. 02	Intellia Therapeutics Inc increases at-the-market offering program to $1.04 billion - SEC filing	RE
Mar. 02	Intellia Shares Jump Premarket After FDA Removes Hold on Clinical Trial	DJ
Mar. 02	Intellia gets FDA nod to resume second gene therapy trial after safety pause	RE
Mar. 02	Intellia Therapeutics announces FDA lift of clinical hold on Magnitude phase 3 clinical trial in ATTR-CM	RE
Mar. 02	Intellia Therapeutics, Inc. Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM	CI
Feb. 27	Wedbush Raises Price Target on Intellia Therapeutics to $12 From $7, Keeps Neutral Rating	MT
Feb. 26	Intellia Therapeutics, Inc., Q4 2025 Earnings Call, Feb 26, 2026
Feb. 26	Intellia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI